Condition
Muscular Dystrophy, Oculopharyngeal
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Completed2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02878694Phase 2TerminatedPrimary
Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft
NCT00773227Phase 2CompletedPrimary
Treatment of Dysphagia in Oculopharyngeal Muscular Dystrophy by Autologous Transplantation of Myoblasts
NCT00001871Completed
Study of Muscle Abnormalities in Patients With Specific Genetic Mutations
Showing all 3 trials